Introduction
Methods
Study Design
Compliance with Ethics Guidelines
Definitions
Statistical Analysis
Results
Microorganism | Number (%)a
|
---|---|
Staphylococcus aureus
| 9 (17) |
Methicillin-susceptible | 4 |
Methicillin-resistant | 5 |
Coagulase-negative staphylococci | 33 (61) |
Methicillin-susceptible | 10 |
Methicillin-resistant | 23 |
Enterococcus faecalis
| 4 (7) |
Streptococcus viridans
| 2 (4) |
Enterobacteriaceaeb,c
| 5 (9) |
Pseudomonas aeruginosa
c
| 1 (2) |
Characteristics | Receiving rifampicin (n = 22) | Not receiving rifampicin (n = 17) |
P
|
---|---|---|---|
Median (IQR) age | 71 (63–75) | 75 (66–77) | 0.31 |
Male sex (%) | 9 (41) | 9 (53) | 0.45 |
Diabetes mellitus (%) | 6 (27) | 3 (18) | 0.37 |
Type of implant (%) | 0.50 | ||
Hip prosthesis | 7 (32) | 6 (35) | |
Knee prosthesis | 15 (68) | 10 (59) | |
Shoulder prosthesis | – | 1 (6) | |
Age of prosthesis | 30 (21–55) | 24 (17–32) | |
Late acute infections (%) | 2 (9) | 2 (12) | 1 |
Median (IQR) days of symptoms before debridement | 9 (3–25) | 2 (1–22) | 0.14 |
Fever (%) | 3 (14) | 2 (12) | 1 |
Bacteremia (%) | 2 (9) | 1 (6) | 1 |
Median (IQR) leukocyte count (cells/mm3) | 8,400 (6,400–9,600) | 6,950 (5,750–8,125) | 0.18 |
Median (IQR) C-reactive protein (mg/dL) | 4 (2–11) | 3 (1–5) | 0.22 |
Microorganisms | |||
S. aureus (MR) | 6 (5) | 3 (0) | |
CoNS (MR) | 18 (13) | 15 (10) | |
E. faecalis
| 3 | 1 | |
S. viridans
| 1 | 1 | |
Enterobacteriaceae | 2 | 3 | |
P. aeruginosa
| 1 | – | |
Polymicrobial (%) | 9 (41) | 6 (35) | 0.50 |
Adverse events | 9 (41) | 8 (47) | |
Gastrointestinal (nausea, vomits or diarrhea) | 7 (32) | 3 (18)a
| |
Hematological toxicity | 1 (5) | 4 (24) | |
Peripheral neuropathyb
| 1 (5) | 1 (6) | |
Outcome (%) | |||
Remission | 14 (64) | 14 (82) | 0.28 |
Relapse | 6 (27) | 2 (12) | |
New infection | 2 (9) | 1 (6) | |
Median (IQR) days of follow-up from stopping antibiotics to the last visit | 730 (161–1,219) | 812 (618–1,362) | 0.39 |